The enzyme at Protein Kinase C (PKC) is essential for a number of cellular activities, including cell survival, multiplication and migration – activities that require careful management of cells t Theft and control. Researchers at the California San Diego University of Medicine found that another enzyme, called PHLPP1, works as a "pilot" to watch carefully tapped PKCs. In pancreatic cancer, they found that high levels of PHLPP1 are continuing to low PKC levels, which relate to poor patient survival.
The audit, published in March 20, 2019 Moilecular Cell, which sets the standard at which single day clinicians use PHLPP1 / PKC standards for pancreatic cancer as predictable for prognosis, and for researchers to develop new medicines that are prevents PHLPP1 and strengthens PKC as a way of managing the disease.
Their investigations were conducted by Alexandra Newton, Ph.D., professor of the Pharmacology Department at UC San Diego Medical School, and Timothy Baffi, a graduate student in her laboratory.
In 2015, Newton's team changed a big house of 30 years when they said evidence that PKC was down, rather than promoting, interests. For decades before this exhibition, many researchers had sought to develop drugs that prevented PKC as a way of treating cancer. Their investigation meant that anti-cancer drugs had to be performed on the other side – the vitality of the PKC process.
Newton's and Baffi's latest research is taking the study further later by describing how cells control PKC's activity. They found that an PKC that is too active will be accidentally removed, at any time, for the “proofer” PHLPP1 to destroy it.
"This means that the PHLPP1 level in your cells decides what level you are of PKC," Newton said. "And it goes out that the levels are very important in pancreatic cancer."
Researchers worked with Gordon Mills, Ph.D at OHSU Knight Cancer Institute to carry out an audit of a database of data data that also includes information on related patients. every tumor. Among the 105 pancreatic shops imported into the database, those with high levels of probation had low levels of PKC.
Moreover, PHLPP1 / low PKC – linked to bad poetry: the live database did not contain a pancreatic patient with a lower PKC in longer than five and a half years. On the other hand, 50 per cent of patients with PHLPP1 / high PKC lasted longer.
Although still at the early stages, Newton hopes that this information could one day support the pancreatic medicine and healing.
"If we can test patients with pancreatic cancer and know that their high PHLPP1 and PKC are low, we would know that the prognosis is not good," Newton said. "And we might hinder PHLPP1, restore PKC work and eventually have the chance to stay."
Newton's team and colleagues will expect to install chemical shapes to detect those removing PHLPP1 and recover PKC levels in PKC-pancreatic cancer cell cells. the laboratory. These could form the basis of a new medicinal drug for pancreatic cancer.
Finding a new route to stop metastasis
University of California – San Diego
Balance of two pancreatic cancer living enzymes (2019, March 20) t
returned 20 March 2019
This document is subject to copyright. In addition to any fair treatment for private research or research purposes, you do not
part can be used without written permission. Content is provided for information purposes only.